AI assistant
Sending…
Roivant Sciences Ltd. — Director's Dealing 2026
Feb 25, 2026
30587_dirs_2026-02-24_0cccc15e-eaaf-469d-b916-59e96bb3a288.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2026-02-20
Reporting Person: Venker Eric (President & Immunovant CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-20 | Common Shares | F | 7051 | $27.15 | Disposed | 1647546 | Direct |
Footnotes
F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
More from Roivant Sciences Ltd.
Registration Form
2026
May 20
Annual Report
2026
May 20
Regulatory Filings
2026
May 20
Regulatory Filings
2026
Apr 2
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 25
Director's Dealing
2026
Mar 25
Regulatory Filings
2026
Mar 23
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 18